APG-115 was recently demonstrated to be sensitive to cancer cells with wild-type p53, whereas it is less effective in p53 mutant DLBCL, AML, and ALL cells (Luo et al., 2020; Zhai et al., 2023). Here, TP53 is linked to acute myeloid leukemia.